Cure rate for experimental hepatitis C drug tops 95 percent

April 10, 2014 by Steven Reinberg, Healthday Reporter
Cure rate for experimental hepatitis C drug tops 95 percent
But high costs of newer medications is a concern, experts say.

(HealthDay)—Researchers report that an experimental drug has cured more than 95 percent of patients infected with hepatitis C, including some who failed other treatments.

If it wins approval from the U.S. Food and Drug Administration, this new drug, called ABT-450, could potentially compete with another innovative hepatitis C medication that costs $1,000 a day.

Nearly 3 million Americans have hepatitis C, a disease that can cause liver cirrhosis and cancer.

These newer, advanced treatments are better-tolerated and easier to take than interferon, the traditional standard treatment for hepatitis C, researchers say.

"Interferon is no longer required to cure hepatitis C," said Dr. Stefan Zeuzem, a professor of medicine at the J.W. Goethe University Hospital in Frankfurt, Germany, and lead researcher on the ABT-450 study.

His research pairing ABT-450 with other interferon-free medications showed "almost all patients with C can be cured even if previous treatments were unsuccessful," Zeuzem said.

The report was published online April 10 in the New England Journal of Medicine, to coincide with presentation of the findings at the annual meeting of the European Association for the Study of the Liver in London. The drug trial was funded by the drug's maker, AbbVie.

"Hepatitis C is a big, bad problem," said Dr. William Carey, a liver specialist at the Cleveland Clinic in Ohio.

This new drug represents "one among many breakthroughs in our ability to deal with hepatitis C," Carey said.

An advantage to this treatment is that it is a pill, while interferon is given in weekly injections. Also, older treatments went on for a year, while this new therapy takes only three months to work, Carey said.

Interferon treatment also has severe side effects, including fatigue and flu-like symptoms.

"This is not the only drug combination that is interferon-free, but it's a very promising one," he said.

One drawback to the therapy is that some pills are taken once a day and some twice, which might make following the treatment tricky. Carey hopes that treatment eventually is simplified. "Wouldn't it be great if we could take one or two pills once a day and be done with it?" he said.

Since many people with hepatitis C remain symptom-free, the medical community has not agreed on whom to treat.

With these new cures, that question becomes easier to answer, Carey said. "When you have a treatment that is this simple, effective and free of side effects, there are fewer and fewer reasons to think about withholding treatment," he noted.

"The major barrier is cost," he added.

Whether the new drug will be priced like Sovaldi, the $1,000-a-day medication, is still unknown.

With Sovaldi, the necessary three-month course costs $90,000, plus any other drug expenses and medical care.

Carey said some insurance companies cover the cost of the drug, while others have denied it.

Cost is even more significant in light of the millions of Baby Boomers who are five times more likely to be infected with hepatitis C than other adults, according to the U.S. Centers for Disease Control and Prevention.

"It's going to get harder as time goes on for insurance companies not to cover the cost of these drugs," Carey said. "This is a curable disease."

According to a CBS News report, lawmakers and complain that Gilead Sciences, the maker of Sovaldi, is trying to "milk desperate patients." Gilead says that, despite the high price, Sovaldi is cheaper because it "cures patients quickly and eliminates a long and expensive treatment using other drugs."

For this phase 3 trial of ABT-450—typically the last trial needed for FDA approval—nearly 400 patients were randomly assigned to take a placebo or a pill containing ABT-450 plus the drugs ombitasvir and ritonavir. These patients also took two additional drugs, dasabuvir and ribavirin.
All patients had been treated before, but saw their diseases return or had a poor response or no response to treatment.

Taking the ABT-450 combination, 96.3 percent of the patients responded, the researchers said.

Previous research showed that who had never been treated also responded to this combination.

Dr. Marc Siegel, an associate professor of medicine at NYU Langone Medical Center, New York City, said the results look promising for the millions of people with hepatitis C.

"Hepatitis C is under-diagnosed," said Siegel.

These new treatments, with their high cure rates, make it important to diagnose and treat C early to prevent cirrhosis and liver cancer, he said.

Hepatitis C can be spread by injectable use or sexual contact with an infected person. The U.S. Centers for Disease Control and Prevention recommends one-time screening for those born between 1945 and 1965—that's potentially millions of people who would qualify for .

Explore further: US approves breakthrough hepatitis C drug (Update)

More information: For more information on hepatitis C, visit the U.S. National Library of Medicine.

Related Stories

US approves breakthrough hepatitis C drug (Update)

December 6, 2013
U.S. health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences Inc. that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.

Doctor details two new hepatitis C drugs

December 20, 2013
In the last three weeks, the Food and Drug Administration has approved two new drugs that are expected to dramatically improve treatment of chronic hepatitis C, a liver-damaging viral infection that afflicts more than 3.2 ...

Medical groups question price of new hep C drug

March 11, 2014
An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer ...

US panel backs Gilead Sciences' hepatitis C drug (Update)

October 23, 2013
U.S. Food and Drug Administration advisers on Friday unanimously voted in favor of a highly anticipated hepatitis C drug from Gilead Sciences that holds promise for millions infected with the liver-destroying virus.

FDA approves new treatment for hepatitis C infection

November 25, 2013
(HealthDay)—The U.S. Food and Drug Administration has approved a new drug for chronic hepatitis C infection that some experts hope will cut down on side effects from current therapies.

More drugs show promise in fighting hepatitis C

August 15, 2013
(HealthDay)—An experimental drug duo may cure some cases of the liver disease hepatitis C, without the severe side effects of standard therapy, a new clinical trial suggests.

Recommended for you

Four simple tests could help GPs spot pneumonia and reduce unnecessary antibiotics

November 23, 2017
Testing for fever, high pulse rate, crackly breath sounds, and low oxygen levels could be key to helping GPs distinguish pneumonia from less serious infections, according to a large study published in the European Respiratory ...

New approach to tracking how deadly 'superbugs' travel could slow their spread

November 22, 2017
Killer bacteria - ones that have out-evolved our best antibiotics—may not go away anytime soon. But a new approach to tracking their spread could eventually give us a fighting chance to keep their death toll down.

Research points to diagnostic test for top cause of liver transplant in kids

November 22, 2017
Biliary atresia is the most common cause of liver transplants for children in the United States. Now researchers report in Science Translational Medicine finding a strong biomarker candidate that could be used for earlier ...

Metabolites altered in chronic kidney disease

November 22, 2017
Chronic kidney disease (CKD) affects 1 in 7 people in the United States, according to the U.S. National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK). These individuals have a very high risk of cardiovascular ...

Alcohol consumption and metabolic factors act together to increase the risk of severe liver disease

November 22, 2017
A new study provides insights into the interaction between alcohol consumption and metabolic factors in predicting severe liver disease in the general population. The findings, which are published in Hepatology, indicate ...

Rainfall can indicate that mosquito-borne epidemics will occur weeks later

November 22, 2017
A new study demonstrates that outbreaks of mosquito-borne viruses Zika and Chikungunya generally occur about three weeks after heavy rainfall.Researchers also found that Chikungunya will predominate over Zika when both circulate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.